drugset / Trial / NCT04271306
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase Ib age de-escalation and dose escalation open label clinical trial of the safety, immunogenicity and ex-vivo efficacy of a candidate malaria vaccine Pfs25-IMX313/Matrix-M administered intramuscularly in healthy adults and young children in Tanzania
Timeline
- Start
- 2021-05-25
- Primary completion
- 2024-02-19
- Completion
- 2024-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pfs25-IMX313 | Vaccine | 10 ug | Intramuscular |
| Subject | Pfs25-IMX313 | Vaccine | 50 ug | Intramuscular |
| Background | Matrix-M1 Adjuvant | Other / unclassified | 50 ug | Intramuscular |